

# Xiaojiao Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9596797/publications.pdf>

Version: 2024-02-01

3  
papers

31  
citations

2258001

3  
h-index

2550070

3  
g-index

3  
all docs

3  
docs citations

3  
times ranked

49  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 615-623.	2.3	15
2	A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 167-174.	0.6	11
3	A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 465-474.	2.3	5